Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Orilissa elagolix CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Keytruda Pembrolizumab CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Lynparza Olaparib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Viibryd vilazodone Depression, Major depressive disorder CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imbruvica ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Revolade eltrombopag CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Symdeko tezacaftor/ivacaftor CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Oncaspar pegaspargase Adult Acute Lymphocytic Leukemia (ALL) Unable to recommend reimbursement Not filed
Zevalin iIbritumomab tiuxetan Non-Hodgkin’s Lymphoma (NHL) Unable to recommend reimbursement Not filed
Latuda lurasidone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imbruvica ibrutinib Leukemia Unable to recommend reimbursement Not filed
Atriance Nelarabine Cancelled
Demylocan decitabine Myelodysplastic Syndromes Unable to recommend reimbursement Not filed
Xarelto Rivaroxaban (granules for oral suspension) Venous Thromboembolic Events CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Admelog Insulin lispro Cancelled
Erbitux Cetuximab Cancelled
TBD Rituximab Cancelled
Translarna ataluren Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
Nucala mepolizumab Eosinophilic granulomatosis with polyangiitis CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Forxiga dapagliflozin Chronic kidney disease CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Emgality galcanezumab Episodic cluster headache CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Clolar clofarabine Acute lymphoblastic leukemia CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Adcetris brentuximab vedotin Hodgkin lymphoma Withdrawn